Everand Logo

Welcome to Everand!

  • STAT

    With eyes on Gilead, lawmakers want details on how HHS reviews possible patent infringement

    After a ruckus over a pricey Gilead Sciences drug for HIV, lawmakers want details on how HHS reviews possible patent infringement.
    by Ed Silverman Jun 18, 2019 3 minutes
    Source: Alex Wong/Getty Images

    A pair of lawmakers has asked the Government Accountability Office to review how the U.S. Department of Health and Human Services manages patents and licenses for medicines that were discovered, at least in part, with taxpayer dollars.

    The move by Sen. Debbie Stabenow (D-Mich.) and Rep. Elijah Cummings (D-Md.) follows a ruckus over a pricey Gilead Sciences () pill for treating and preventing HIV and the role federal government may have played in discovering the medicine, which is

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
    Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
    STAT2 min readAmerican Government
    STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
    The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

    Related Books & Audiobooks